Trump eyes 200% drug tariffs, copper, chips in new trade wave

U.S. trade policy shifts toward “extreme protectionism”
In a bold departure from previous trade tactics, President Donald Trump has unveiled sweeping tariff plans that signal a new era of aggressive economic nationalism. Announced during a July 8, 2025 Cabinet meeting, the policy focuses on protecting three key industries—pharmaceuticals, semiconductors, and copper—through steep tariffs and audits of global supply chains. Trump’s statement that pharmaceutical tariffs “could reach” 200% marks an unprecedented escalation in protectionist measures.

What’s behind the pharmaceutical tariff threat?
In a candid moment with reporters, Trump described a one-year to 18-month grace period for pharmaceutical companies to “get their act together.” After that, “they’re going to be tariffed at a very, very high rate, like 200 per cent”. The tariffs are linked to a broader Section 232 investigation—already underway since April—focused on risks posed by heavy U.S. reliance on foreign-produced APIs (active pharmaceutical ingredients) and finished drugs.

U.S. Commerce Secretary Howard Lutnick echoed Trump, indicating concrete details would emerge by the end of July, following the ongoing study. These steep duties aim to force pharmaceutical re-shoring or production relocation, addressing vulnerability in national supply chains exposed by past shortages.

Semiconductors and copper: part of the same strategy
Trump also announced plans for steep tariffs on semiconductors and copper. He reiterated intentions for a 50% tariff on copper imports, and an impending semiconductor tariff under the same Section 232 framework. This trifecta—drugs, chips, and metals—suggests an industrial policy that places national and economic security at its core, aiming to revive domestic manufacturing.

Economic risks and volatility ahead
Market reactions were swift: Wall Street opened mixed, with tech and industrial stocks lagging as traders digested the tariff announcement . History shows such moves can trigger global supply chain disruption and higher consumer prices—concerns likely to re-emerge if pharmaceutical prices spike after the one-year deadline.

Global shockwaves: Canada, Mexico, Australia on alert
This move won’t stay confined to the U.S. Canada and Mexico—already embroiled in earlier 2025 trade wars—face mounting scrutiny. Prior U.S. tariffs on steel, aluminum, and auto goods have already strained cross-border commerce and political ties under USMCA . Now, Canada’s pharmaceutical and tech industries may face rising barriers, potentially triggering fresh retaliation or supply chain relocation.

Australia has also voiced strong concern. With pharmaceuticals making up 20% of its exports to the U.S., the specter of up to 200% tariffs threatens major drugmakers like CSL. Australian leaders, including Prime Minister Albanese and Treasurer Chalmers, have jointly called out the tariffs as “extremely harmful,” pledging to shield their Pharmaceutical Benefits Scheme (PBS) and demanding exemptions. Australia is prepared to contest tariffs under existing agreements if necessary.

Historical context—trade war redux
It’s not the first time Trump has used tariffs aggressively: his 2018-19 steel and aluminum tariffs rattled global markets. His previous rounds drew broad criticism, with economists warning of recession risk. But Trump seems to consider this iteration different, framing it as a strategic move to strengthen U.S. industrial resilience .

Manufacturers scramble to respond
Pharmaceutical manufacturers and the tech industry are bracing for the fallout. Re-shoring production is expensive and slow; supply chains are complex and involve multiple international actors. The announced grace period gives them time, but the task is monumental. U.S. drug importers are preparing contingency plans to minimize cost transfers to consumers, while trading partners explore legal recourse and alternate markets.

Public health and consumer implications
Tariffs of this magnitude could have serious public health consequences. Medicines that were already expensive could double in cost—or evaporate from store shelves. Consumer advocates warn that such tariffs—designed to pressure corporates—will instead fall hardest on everyday patients reliant on affordable meds.

Semiconductors and copper: foundations of supply security
Semiconductors and copper are critical inputs for everything from smartphones to EVs. This administration sees tariffs as a tool to incentivize the construction of domestic chip fabs and metal processing facilities. But these projects take years and trillions of dollars in infrastructure. Without clear follow-through plans and investment, opportunistic tariffs risk producing more supply shock than renewal .

Political dimensions heading into 2026
The tariff announcement plays into Trump’s political narrative of putting “America First”—appealing to industrial workers and rural manufacturers. It strengthens his campaign messaging by tapping public frustration over job losses, outsourcing, and China’s global might.

But Democrats and even Republicans warn that tariffs could backfire politically if consumers bear higher costs. Healthcare affordability is already a hot-button issue, and steep drug tariffs could amplify fears.

Legal nuance and trade agreements
The administration plans to invoke Section 232 of the Trade Expansion Act for both drugs and chips—a law permitting national-security tariffs. The law is controversial, as it bypasses congressional consent and international trade norms. Critics argue this legal strategy may invite dispute under the WTO or USMCA arrangements .

Global alliances confront a tidal shift
Allies from Europe to Asia are watching this unfold. A wave of country-specific protections—particularly on commodities like copper or strategic goods like chips—could splinter the postwar global trade system. If major economies follow suit, we could see higher regionalization or bloc-based protection replacing decades of globalization.

What’s next: regulatory follow-up, policy cadence
The month ahead will be pivotal: Commerce Department research deadlines loom, and traders, manufacturers, healthcare companies, and European allies are expecting policy clarity by late July. The actual implementation timeline, threshold price triggers, carve-outs—for example, chronic drug treatments—will determine the extent of economic disruption.

Broader economic and social seed effects
The era of cheap, widely distributed supply chains is under review. Tariffs will likely ripple into stock portfolios, medical affordability, tech innovation costs, and global diplomatic alliances. If sustained, they may reshape manufacturing, energy, and resource allocation decisions for decades.